National Diabetes Education Initiative :: Continuing Education (CME)

Home About NDEI Site Map FAQ Contact Us Feedback

Advanced Search

User Name

Password

Remember me

Forgot Password?

Your Online Resource for Diabetes Treatment

Welcome to NDEI.org, the website of the National Diabetes Education Initiative. Register

May 9, 2008

What's New

CCMDweb.org Interactive Case Study
Secondary Prevention of Cardiovascular Disease:
Looking Beyond the LDL
Knowledge of appropriate management of patients with type 2 diabetes and established coronary artery disease

Faculty: Peter Libby, MD

1.5 AMA PRA Category 1 Credits™

New Slides of the month
View our Slide Library. The NDEI Slide Library includes slides on type 2 diabetes and related topics. All are searchable by topic, author, title, keywords, and slide notes. Slides can be downloaded directly to your hard drive or emailed to you.

Changing Paradigms in the Prevention and Treatment of Type 2 Diabetes: Results From Recent Pivotal Trials

Faculty: Edward S. Horton, MD; Hertzel C. Gerstein, MD, MSc, FRCPC; Steven M. Haffner, MD; Theodore Mazzone, MD

The Endocrine Society designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™.

Live Activities

Dinner Meetings
Managing the Complexities of Type 2 Diabetes:
A Roadmap for Improving Patient Care
A Case-Based Interactive CME/CE Dinner Program

Tuesday, March 18, 2008	San Antonio, Texas
Thursday, March 20, 2008	Baltimore, Maryland
Wednesday, March 26, 2008	Seattle, Washington
Tuesday, April 8, 2008	New Orleans, Louisiana
Tuesday, April 8, 2008	Richmond, Virginia
Wednesday, April 9, 2008	Atlanta, Georgia
Thursday, April 10, 2008	Orlando, Florida
Tuesday, April 15, 2008	Cincinnati, Ohio
Thursday, April 17, 2008	Ann Arbor, Michigan
Tuesday, April 22, 2008	Rochester, New York
Thursday, April 24, 2008	Stamford, Connecticut
Tuesday, April 29, 2008	Indianapolis, Indiana
Tuesday, May 6, 2008	St Louis, Missouri
Thursday, May 29, 2008	Denver, Colorado
Thursday, May 29, 2008	Birmingham, Alabama

On Demand Activities

Diabetes Expert Forum—The Role of Incretin Therapy in Your Practice
Faculty: Mark W. Stolar, MD; Silvio E. Inzucchi, MD; Frank Lavernia, MD

1.75 AMA PRA Category 1 Credits™

This activity has been reviewed and is acceptable for up to 2.75 Prescribed credits by the American Academy of Family Physicians

Type 2 Diabetes, Metabolic Syndrome, and CVD: Clinical Implications of Recent Pivotal Trials
Presented by Silvio E. Inzucchi, MD Professor of Medicine Yale University School of Medicine New Haven, Connecticut

Incretins and Glycemic Control: Understanding the Science for Better Diabetes Management
Presented by: Edward Horton, MD (Chairman), Charles Burant, MD, PhD, and John Buse, MD, PhD

Interactive Case Studies


	A 54-Year-Old Taxi Driver Who Presents for Reassessment of His Type 2 Diabetes and New Dyspnea on Exertion Authored by Silvio E. Inzucchi, MD Earn 0.75 AMA PRA Category 1 Credit™-Free

FDA Alerts

FDA Adds Boxed Warning for Heart-related Risks to Anti-Diabetes Drug Avandia

11/14/07
The U.S. Food and Drug Administration announced today that the manufacturer of Avandia (rosiglitazone), a drug used to treat type 2 diabetes, has agreed to add new information to the existing boxed warning in the drug's labeling about potential increased risk for heart attacks.

People with type 2 diabetes who have underlying heart disease or who are at high risk of heart attack should talk with their health care provider about the revised warning as they evaluate treatment options. FDA advises health care providers to closely monitor patients who take Avandia for cardiovascular risks.

Click here to view the entire press release.

Quick Links to the Most Timely Content on the Internet

The links below search the National Library of Medicine's Medline database (PubMed) for abstracts posted during the previous 7 calendar days. The links are updated daily to reflect the addition of new content.

Please contact us through info@ndei.org with suggestions for additional search terms.

Search for new abstracts posted within the past:

•	Insulin Resistance	•	Patient Management	•	Alpha-Glucosidase Inhibitors
•	Metabolic Syndrome	•	Novel Therapies	•	Diabetes and Statins
•	Diabetes and Cardiovascular Disease	•	Thiazolidinediones	•	Diabetes and ACE Inhibitors
•	Beta-cell Function	•	Biguanides	•	Diabetes and Dyslipidemia
•	Glycemic Control	•	Sulfonylureas	•	Epidemiology of Diabetes

Sponsored by
Professional Postgraduate Services ^®
Secaucus, NJ

Supported by educational grants from Takeda Pharmaceuticals North America, Inc. and Merck & Co., Inc.

Click Here for 2008 ADA Guideline Slides

Click Here for Current Slides of the Month

Click Here for Archived Slides of the Month

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M.
Curr Med Res Opin. 24(2):537-50

Sitagliptin: a novel agent for the management of type 2 diabetes mellitus
Pham DQ, Nogid A, Plakogiannis R
Am J Health Syst Pharm. 65(6):521-31

Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
Azuma K, Rádiková Z, Mancino J, Toledo FG, Thomas E, Kangani C, Dalla Man C, Cobelli C, Holst JJ, Deacon CF, He Y, Ligueros-Saylan M, Serra D, Foley JE, Kelley DE.
J Clin Endocrinol Metab. 93(2):459-64

Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study
Bolli G, Dotta F, Rochotte E, Cohen SE
Diabetes, Obesity and Metabolism. 10(1):82-90

Supported by educational grants from Takeda Pharmaceuticals North America, Inc. and Merck & Co., Inc.
Professional Postgraduate Services is a business unit of KnowledgePoint360 Group, LLC, Secaucus, NJ.
Copyright © 2007 Professional Postgraduate Services®. All rights reserved. - Disclaimer Statement - Privacy Statement